FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Sebastian Stintzing, Florian Kaiser et al.|British Journal of Cancer|2020Cited by 187
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studySebastian Stintzing, Volker Heinemann, Lisa Miller‐Phillips et al.|European Journal of Cancer|2017Cited by 139